Cannabis Bioscience International Holdings Inc (CBIH) is a cannabis education and bioscience company that operates instructional seminars, cannabis training programs, and early-stage cannabinoid research. Revenue is generated through fees from educational courses and seminars targeting physicians, attorneys, nurses, insurance agents, and business professionals on medical cannabis regulatory frameworks. The company operates under its Pharmacology University brand, offering courses that carry CLE and CME accreditation from state bar associations and medical education bodies in Arkansas, Oklahoma, and Texas (as of the 10-K filed 2025-09-22). CBIH also pursues cannabinoid drug development, holding multiple U.S. patent applications filed in late 2024 covering cannabinoid compositions for conditions including depression, anxiety, multiple sclerosis, and respiratory viral infections. The company has conducted seminars across Texas, Arkansas, Florida, Illinois, Missouri, Oklahoma, Georgia, Puerto Rico, Mexico, Peru, Ecuador, Colombia, and the Dominican Republic, though active in-person programming as of the filing date is concentrated in Texas. Dante Picazo has served as CEO and CFO since 2019.

Revenue model

Tuition and seminar fees from cannabis education courses targeting licensed professionals and the general public, with certificates of completion awarded upon finishing non-accredited coursework. The company also intends to sell or license cannabinoid drug candidates if clinical development succeeds, but no product licensing revenue is reported in the filing.

Products and services

Cannabis education seminars and courses delivered under the Pharmacology University brand, including a 130-hour semester-length course offered at the University of Tadeo in Colombia awarding a 'Diplomado en Cannabis' certificate. CLE-accredited courses approved in Arkansas, Oklahoma, and Texas. CME-accredited courses approved in Arkansas. Planned seminar series in Houston, Dallas, San Antonio, El Paso, and Brownsville tied to Texas House Bill 46. Early-stage cannabinoid patent applications filed October through November 2024 covering compositions for depression, anxiety, multiple sclerosis, oral health, and respiratory viral infections.

Customers and end markets

Licensed professionals including physicians, attorneys, nurses, insurance agents, dietitians, and veterinarians seeking CLE or CME credits. Business leaders and entrepreneurs in cannabis-adjacent industries. General public and patients seeking cannabis education. End market demand is tied to state-level medical cannabis regulatory expansion, particularly Texas TCUP and House Bill 46.

Value-chain role

Education and training provider at the intersection of cannabis regulation and licensed professional development. Early-stage drug developer seeking to progress cannabinoid compositions through clinical trials with intent to sell or license resulting IP.

Geographic exposure

Active in-person educational programming in Texas as of the 10-K filed 2025-09-22. Prior seminar activity in Arkansas, Florida, Illinois, Missouri, Oklahoma, Georgia, and Puerto Rico in the United States. International seminar history in Mexico, Peru, Ecuador, Colombia, and the Dominican Republic, including a partnership with Jorge Tadeo Lozano University in Bogota and Cartagena.

Source: SEC 10-K, filed 2025-09-22

Industry: Services-Commercial Physical & Biological Research Peers: BNB Plus Corp PRESSURE BIOSCIENCES INC Telesis Bio Inc. Reflect Scientific Inc RADNOSTIX, INC. Science 37 Holdings, Inc. Singular Genomics Systems, Inc. Thermo Fisher Scientific Inc